BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
MIGDAL HA'EMEQ, Israel, July 26, 2017 -- Enzymotec Ltd. (Nasdaq:ENZY) (“Enzymotec” or the “Company”), a developer, manufacturer and marketer of innovative bio-active lipid ingredients and medical foods, announced today that the Company will release financial results for the second quarter ended June 30, 2017 on Wednesday, August 16, 2017, before the market opens. Following the release, Erez Israeli, President and Chief Executive Officer, and Oren Bryan, Vice President and Chief Financial Officer, will host a conference call to review the financial results.
The conference call is scheduled to begin at 8:30 am ET on Wednesday, August 16, 2017. Participants should dial +1 877-359-9508 (United States) or +1 224-357-2393 (International) with confirmation code #54908799 to access the live call. The call will also be broadcast live over the Internet, hosted in the Investors section of Enzymotec's website at http://edge.media-server.com/m/p/fsb2hqfy, and will be archived online within one hour of its completion.
About Enzymotec Ltd.
Enzymotec is a leading global supplier of specialty lipid-based products and solutions. The Company develops, manufactures and markets innovative bio-active lipid ingredients, as well as final products, based on sophisticated processes and technologies.
Company Contact Enzymotec Ltd. Oren Bryan Chief Financial Officer Phone: +972747177177 [email protected] Investor Relations Contact (U.S.) The Ruth Group Tram Bui / Alexander Lobo Phone: 646-536-7035 / 7037 [email protected] [email protected]
